FDA Approves Mirum and Incyte's Atebrioz for Rare Bone Disorder FOP
The U.S. Food and Drug Administration (FDA) approved the drug Atebrioz, also known as zilurgisertib, developed by Mirum Pharmaceuticals (MIRM) in collaboration with Incyte Corporation (INCY), to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder that causes bone formation within muscles and connective tissues. The therapy aims to reduce the volume of new heterotopic ossification, offering hope for patients suffering from this debilitating condition. This approval marks an important milestone in addressing unmet medical needs among individuals with ultra-rare diseases. Both Mirum Pharmaceuticals and Incyte are expected to benefit financially as Atebrioz becomes available on the market under FDA clearance.
